Scleromyxoedema: Treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin

A. Kulczycki, M. Nelson, A. Eisen, M. Heffernan

Research output: Contribution to journalArticlepeer-review

44 Scopus citations


Scleromyxoedema is a rare disease characterized by cutaneous sclerosis, mucin deposition and paraproteinaemia. Internal disease is common, particularly musculoskeletal, gastrointestinal and central nervous system involvement. We report a series of three consecutive patients with scleromyxoedema treated with high-dose intravenous immunoglobulin (hdIVIg). Each of the three patients had relatively low levels of a highly basic IgG-λ paraprotein, and each has demonstrated a sustained response of both their cutaneous and extracutaneous disease to hdIVIg. As all patients had perioral skin involvement and microstomia, one measure of cutaneous improvement was the increase in intraincisor distance. Extracutaneous manifestations of scleromyxoedema that improved included ureteral stricture, vocal strength and dysphagia.

Original languageEnglish
Pages (from-to)1276-1281
Number of pages6
JournalBritish Journal of Dermatology
Issue number6
StatePublished - Dec 2003


  • Case series
  • Intravenous immunoglobulin
  • Paraprotein
  • Scleromyxoedema


Dive into the research topics of 'Scleromyxoedema: Treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin'. Together they form a unique fingerprint.

Cite this